-
05:59:50 PM

VRTX Stock News

03/16/23 8:00 AM
Nasdaq : VRTX
clinical trial
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
Vertex Pharmaceuticals Incorporated today announced publication in the New England Journal of Medicine of results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin on top of standard-of-care in people with focal segmental glomerulosclerosis and two APOL1 variants, a severe, rapidly progressive form of...
RHEA-AI
neutral
03/09/23 8:00 AM
Nasdaq : VRTX
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug Application for VX-264, a stem cell-derived, fully differentiated pancreatic islet cell therapy encapsulated into a Vertex- developed, immunoprotective device with the potential to treat type 1 diabetes.
RHEA-AI
neutral
03/01/23 6:25 AM
Nasdaq, NYSE : IMGN, VRTX
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates, today announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals rights to conduct research using ImmunoGen's ADC technology to discover novel targeted conditioning agents for use with gene editing. As part of the agreement, Vertex...
RHEA-AI
very positive
12/12/22 8:00 AM
Nasdaq : VRTX
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VX-522, a messenger ribonucleic acid therapy targeted at treating the underlying cause of cystic fibrosis lung disease for the approximately 5,000 people with CF who cannot benefit from a cystic...
RHEA-AI
very positive
12/08/22 7:00 AM
Nasdaq : VRTX, TRDA
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle therapeutics for myotonic dystrophy type 1. “Vertex’ s strategy is to discover and develop transformative medicines for people with serious diseases, and DM1 has...
RHEA-AI
positive